By Elric Langton & Alex Langton | 24 March 2024
Mike, Alex and Elric have a financial interest in SkinBioTherapeutics.
In a seismic development poised to redefine the contours of the cosmetics, skincare, and wound care markets, SkinBioTherapeutics has provided us with an example of the madness of AIM by heralding the nearing culmination of its pioneering 'Intel Inside' active ingredient, promising to chart a new trajectory in science-based evidence application in these sectors. Yesterday, we focused on the Croda/Sederma partnership and will revisit it today. We will also delve into the interim report, including significant clues we discussed yesterday. Stuart Ashman, the Company's CEO, elaborated on these details during the investor presentation on Friday. The announcement, signifying a quantum leap towards commercialising this groundbreaking innovation to the symbiotic alliance between SkinBioTherapeutics and the Croda/Sederma, marks a watershed moment in SkinBioTherapeutics and the industry; it also validates stubborn investors' aspirations for the event.